deoxycytidine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, H; Furman, PA; McBrayer, TR; Micolochick Steuer, HM; Murakami, E; Obikhod, A; Otto, MJ; Ramesh, M; Schinazi, RF; Stuyver, LJ; Whitaker, T | 1 |
| Kent, KM; Oliyai, R; Yang, T | 1 |
| Cao, S; Stephenson, AA; Suo, Z; Taggart, DJ; Vyavahare, VP | 1 |
| Ballester, R; Bernaards, C; Bertasso, A; Dwyer, C; Gane, EJ; Hammond, J; Kindrick, A; Marcellin, P; Morcos, PN; Nájera, I; Pockros, PJ; Shikhman, A; Shulman, NS; Smith, P; Stancic, S; Tong, X; Yetzer, ES; Zeuzem, S; Zhou, J | 1 |
| Back, D; Khoo, S; Seden, K | 1 |
| Alfredson, T; Brandl, M; Chow, J; Comstock, K; Li, F; Lin, F; Liu, Y; Sarma, K | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Lawitz, EJ; Membreno, FE | 1 |
| Dahari, H; Guedj, J; Perelson, AS; Shudo, E; Smith, P | 1 |
| Chatterjee, A; Perelson, AS; Smith, PF | 1 |
| Pockros, PJ | 1 |
| Ingiliz, P; Ivanka, K; Krznaric, I; Martin, O; Obermeier, M; Patrick, I | 1 |
| Amador, A; Benzaria, S; Gosselin, G; Mathieu, S; Moussa, A; Pierra, C; Storer, R | 1 |
| Bearz, A; Berretta, M; Di Benedetto, F; Lleshi, A; Spina, M; Tirelli, U | 1 |
4 review(s) available for deoxycytidine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
The HCV NS5B nucleoside and non-nucleoside inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Hepatitis C viral kinetics: the past, present, and future.
Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, Biological; Oligopeptides; Protease Inhibitors; Pyrrolidines; Silybin; Silymarin; Valine | 2013 |
Nucleoside/nucleotide analogue polymerase inhibitors in development.
Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
2 trial(s) available for deoxycytidine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Topics: Adult; Aged; Cyclopropanes; Deoxycytidine; Electrocardiography; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides | 2015 |
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Topics: Antiviral Agents; Deoxycytidine; Dideoxynucleotides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Theoretical; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2012 |
9 other study(ies) available for deoxycytidine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
Topics: Antiviral Agents; Catalysis; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Mutation; Phosphorylation; RNA-Dependent RNA Polymerase; RNA, Viral; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2007 |
The making of the one pill-Developing single tablet regimens for HIV and for HCV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis C; HIV Infections; Humans; Organophosphonates; Tablets | 2022 |
Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Gemcitabine; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Structure-Activity Relationship; Virus Replication | 2021 |
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline | 2010 |
Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Contamination; Esters; Hepatitis C; Magnetic Resonance Spectroscopy; RNA-Dependent RNA Polymerase; Spectrometry, Mass, Electrospray Ionization | 2010 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
Topics: Acute Disease; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; HIV Seropositivity; Homosexuality, Male; Humans; Male; Organophosphonates; Sulfonamides; Tenofovir; Treatment Outcome; Unsafe Sex; Viral Load | 2013 |
Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.
Topics: Animals; Antiviral Agents; Chemistry, Pharmaceutical; Deoxycytidine; Drug Design; Hepacivirus; Hepatitis C; Humans; Models, Chemical; Prodrugs; Pyrimidine Nucleosides | 2005 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2006 |